Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
258 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05803941 | Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer | recruiting | Phase 4 | 700 | Novartis PharmaceuticalsINDUSTRY | 11 | Jun 4, 2026 | clinicaltrials |
| NCT05890677 | The LYMPH Trial - Microsurgical Versus Conservative Treatment of Chronic Breast Cancer Associated Lymphedema(LYMPH) | recruiting | N/A | 280 | University Hospital, Basel, SwitzerlandOTHER | 15 | Jun 4, 2026 |
| clinicaltrials |
| NCT07627334 | Personalized Targeted Glioblastoma Therapies by ex Vivo Drug Screening: Advanced Brain Tumor TheRApy Clinical Trial In Patients Scheduled for shOrt Course radiatioN(ATTRACTION) | recruiting | N/A | 30 | Medical University of ViennaOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT06369831 | HER2 Targeted Molecular Imaging in mBC and Other Metastatic Solid Carcinomas Using 68Ga-ABS011(HERMIA) | recruiting | Phase 2 | 60 | Abscint NV/SAINDUSTRY | 2 | Jun 2, 2026 | clinicaltrials |
| NCT06284317 | A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer.(ADOPT-lung) | recruiting | Phase 3 | 290 | ETOP IBCSG Partners FoundationNETWORK | 10 | May 14, 2026 | clinicaltrials |
| NCT05907057 | An Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy. | recruiting | Phase 3 | 245 | Servier Affaires MédicalesINDUSTRY | 4 | May 8, 2026 | clinicaltrials |
| NCT06697301 | Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma. | recruiting | Phase 2 / Phase 3 | 740 | Eikon TherapeuticsINDUSTRY | 24 | May 8, 2026 | clinicaltrials |
| NCT04043494 | International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma(LBL 2018) | recruiting | Phase 3 | 683 | University Hospital MuensterOTHER | 21 | May 6, 2026 | clinicaltrials |
| NCT07015190 | Neoadjuvant Darovasertib in Primary Uveal Melanoma | recruiting | Phase 3 | 520 | IDEAYA BiosciencesINDUSTRY | 21 | May 6, 2026 | clinicaltrials |
| NCT06111105 | GUIDE.MRD-01-CRC: Clinical Validation and Benchmarking of Top Performing ctDNA Diagnostics - Colorectal Cancer | recruiting | — | 590 | Claus Lindbjerg AndersenOTHER | 5 | May 4, 2026 | clinicaltrials |
| NCT05580562 | ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)(ACTION) | recruiting | Phase 3 | 510 | Jazz PharmaceuticalsINDUSTRY | 18 | Apr 16, 2026 | clinicaltrials |
| NCT06512311 | Personalized Targeted Glioblastoma Therapies by ex Vivo Drug Screening(ATTRACT) | recruiting | N/A | 240 | Medical University of ViennaOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT06419946 | Lomustine in Addition to Standard of Care in Patients With MGMT Methylated Glioblastoma | recruiting | Phase 3 | 200 | Vastra Gotaland RegionOTHER_GOV | 4 | Apr 13, 2026 | clinicaltrials |
| NCT06079970 | Confocal Laser Endomicroscopy VERification(CLEVER) | recruiting | N/A | 208 | Amsterdam University Medical Centers (UMC), Location Academic Medical Center (AMC)OTHER | 5 | Apr 7, 2026 | clinicaltrials |
| NCT04294927 | TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention(TUBA-WISP-II) | recruiting | N/A | 3,000 | University Medical Center NijmegenOTHER | 16 | Apr 6, 2026 | clinicaltrials |
| NCT06408441 | The Epithelioid Hemangioendothelioma Registry of the European Reference Network on Rare Adult Solid Cancers (EURACAN)(EHE) | recruiting | — | 100 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 10 | Apr 3, 2026 | clinicaltrials |
| NCT07510724 | Real-World Data on the Treatment of Lung Cancer Patients With the Immune-Checkpoint Inhibitor Tislelizumab(IKF-ReWoLuTe) | recruiting | — | 240 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 2 | Apr 3, 2026 | clinicaltrials |
| NCT07506005 | Anastomotic Bleeding in Colorectal Anastomosis Relating to the Placement of the Stapler Spike to the Staple Line | recruiting | — | 102 | Kepler University HospitalOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT06093672 | Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera(GIV-IN-PV) | recruiting | Phase 3 | 220 | ItalfarmacoINDUSTRY | 16 | Mar 25, 2026 | clinicaltrials |
| NCT06932562 | A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant | recruiting | Phase 3 | 1,000 | European Myeloma Network B.V.NETWORK | 18 | Mar 25, 2026 | clinicaltrials |
| NCT03049072 | Ion Therapy Patient Registry(REGI-MA-002015) | recruiting | — | 2,800 | EBG MedAustron GmbHINDUSTRY | 1 | Mar 23, 2026 | clinicaltrials |
| NCT04894643 | Preoperative, Proton- Radiotherapy Combined With Chemotherapy for Borderline Resectable Pancreatic Cancer(PARC) | recruiting | N/A | 10 | EBG MedAustron GmbHINDUSTRY | 1 | Mar 20, 2026 | clinicaltrials |
| NCT05191940 | Radiotherapy for Locally Advanced Pancreatic Carcinomas (Phase II Trial)(LAPC) | recruiting | N/A | 30 | EBG MedAustron GmbHINDUSTRY | 1 | Mar 20, 2026 | clinicaltrials |
| NCT03590171 | International Study for Treatment of High Risk Childhood Relapsed ALL 2010 | recruiting | Phase 2 | 250 | Charite University, Berlin, GermanyOTHER | 15 | Mar 17, 2026 | clinicaltrials |
| NCT05124236 | Trial of Preoperative Radiosurgery Versus Postoperative Stereotactic Radiotherapy for Resectable Brain Metastases(PREOP-2) | recruiting | N/A | 200 | Susanne RogersOTHER | 3 | Mar 4, 2026 | clinicaltrials |
| NCT05549297 | Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM) | recruiting | Phase 3 | 540 | Immunocore LtdINDUSTRY | 12 | Feb 25, 2026 | clinicaltrials |
| NCT06112314 | IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)(PRISM-MEL-301) | recruiting | Phase 3 | 680 | Immunocore LtdINDUSTRY | 26 | Feb 25, 2026 | clinicaltrials |
| NCT05991388 | A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma(Glo-BNHL) | recruiting | Phase 2 / Phase 3 | 210 | University of BirminghamOTHER | 7 | Feb 20, 2026 | clinicaltrials |
| NCT06446882 | Diagnostic HER2DX-guided Treatment for Patients wIth Early-stage HER2-positive Breast Cancer(DEFINITIVE) | recruiting | N/A | 304 | Fundacio Clinic BarcelonaOTHER | 5 | Feb 20, 2026 | clinicaltrials |
| NCT07423169 | Partial Tumor Irradiation and Immunotherapy for Unresectable Lung Cancer | recruiting | N/A | 10 | Karl Landsteiner University of Health SciencesOTHER | 1 | Feb 20, 2026 | clinicaltrials |
| NCT04202341 | Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs) | recruiting | — | 500 | Alexion Pharmaceuticals, Inc.INDUSTRY | 7 | Feb 18, 2026 | clinicaltrials |
| NCT04833894 | Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis(ADAPT Jr) | recruiting | Phase 2 / Phase 3 | 12 | argenxINDUSTRY | 12 | Feb 18, 2026 | clinicaltrials |
| NCT07418450 | Discrimination of N2a and N2b by EBUS-TBNA: is a Change of the Needle Necessary? | recruiting | N/A | 30 | University of ViennaOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT06298565 | A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa | recruiting | — | 680 | argenxINDUSTRY | 6 | Feb 17, 2026 | clinicaltrials |
| NCT06830759 | Real-World Study to Assess Subcutaneous Epcoritamab in Adult Participants With Diffuse Large B-Cell and Follicular Lymphoma(EpcoReal) | recruiting | — | 700 | AbbVieINDUSTRY | 13 | Feb 17, 2026 | clinicaltrials |
| NCT06435429 | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | recruiting | Phase 3 | 550 | Jazz PharmaceuticalsINDUSTRY | 15 | Feb 10, 2026 | clinicaltrials |
| NCT04895436 | Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)(ReVenG) | recruiting | Phase 2 | 75 | AbbVieINDUSTRY | 11 | Feb 9, 2026 | clinicaltrials |
| NCT02394626 | Surgery for Recurrent Glioblastoma(RESURGE) | recruiting | Phase 2 | 120 | Insel Gruppe AG, University Hospital BernOTHER | 9 | Feb 2, 2026 | clinicaltrials |
| NCT07334301 | A Multi-Arm, Platform Trial For Relapsed Neuroblastoma(BEACON2) | recruiting | Phase 1 / Phase 2 | 160 | University of BirminghamOTHER | 5 | Jan 12, 2026 | clinicaltrials |
| NCT01252485 | Registry Study on Patient Characteristics, Biological Disease Profile and Clinical Outcome in Acute Myeloid Leukemia and Related Neoplasms - The Biology and Outcome (BiO)-Project(AMLSG BiO) | recruiting | — | 50,000 | University of UlmOTHER | 2 | Jan 5, 2026 | clinicaltrials |
| NCT02986516 | Sacral Chordoma: Surgery Versus Definitive Radiation Therapy in Primary Localized Disease(SACRO) | recruiting | N/A | 100 | Italian Sarcoma GroupNETWORK | 10 | Jan 2, 2026 | clinicaltrials |
| NCT06690775 | CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer. | recruiting | Phase 2 | 230 | TORL Biotherapeutics, LLCINDUSTRY | 12 | Dec 23, 2025 | clinicaltrials |
| NCT05259605 | Observational Study for Assessing Treatment and Outcome of Patients With Primary Brain Tumours Using cIMPACT-NOW and 2021 WHO Classification | recruiting | — | 1,650 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 12 | Dec 17, 2025 | clinicaltrials |
| NCT06717919 | HOPE Against Cancer Recurrence in HCC(HOPE4Cancer) | recruiting | Phase 4 | 220 | Philipp DutkowskiOTHER | 17 | Dec 16, 2025 | clinicaltrials |
| NCT06856837 | - IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver Metastases | recruiting | Phase 2 | 140 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 2 | Dec 12, 2025 | clinicaltrials |
| NCT06237803 | European Myeloma Network (EMN) Sample Project(EMN36) | recruiting | — | 6,000 | European Myeloma Network B.V.NETWORK | 10 | Dec 3, 2025 | clinicaltrials |
| NCT05873231 | Role of the Gut Microbiome in Anti-tumor Therapy Induced Diarrhea(TKI) | recruiting | — | 150 | Medical University of GrazOTHER | 1 | Nov 25, 2025 | clinicaltrials |
| NCT06376162 | Ziftomenib in Combination With Chemotherapy for Children With Relapsed/Refractory Acute Leukemia | recruiting | Phase 1 | 20 | PedAL BCU, LLCOTHER | 7 | Oct 20, 2025 | clinicaltrials |
| NCT04111978 | MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO)(MATAO) | recruiting | Phase 3 | 540 | Swiss GO Trial GroupNETWORK | 3 | Sep 29, 2025 | clinicaltrials |
Data updated 22 days agoSource updated unknownsource: clinicaltrials